Australia markets close in 12 minutes

Biocartis Group NV (BCART.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
3.1400-0.0750 (-2.33%)
At close: 05:35PM CET
Full screen
Previous close3.2150
Open3.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.0800 - 3.2000
52-week range3.0800 - 4.9000
Volume179,785
Avg. volume55,100
Market cap180.694M
Beta (5Y monthly)1.67
PE ratio (TTM)N/A
EPS (TTM)-1.2040
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.25
  • GlobeNewswire

    Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES

    PRESS RELEASE: REGULATED INFORMATION10 January 2022, 07:00 CET BIOCARTIS MEETS 2021 KEY OBJECTIVES Mechelen, Belgium, 10 January 2022 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announced the Company has achieved its 2021 key business objectives which were focused on three performance indicators: expanded installed base of its rapid and easy-to-use Idylla™ molecular diagnostics platform, increased Idylla™ commercial

  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant

    PRESS RELEASE: 9 December 2021, 07:00 CET Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant Mechelen, Belgium, 9 December 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the Company performed an in-silico analysis which concluded that the Idylla™ SARS-CoV-2 Test (CE-IVD) and the Idylla™ SARS-CoV-2/Flu/RSV1 Panel (CE-IVD) detect the currently available B.1.1.529/Omicron

  • GlobeNewswire

    Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA

    PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the US Food and Drug Administration (FDA) has granted 510(k) clearance1 for SeptiCyte® RAPID (CE-IVD, US FDA 510(k)). This test runs on Biocartis’ rapid and easy-to-use molecular diagnostics Idylla™ platform2 and was devel